Lord's Mark Partners with ARKALL to Expand Caribbean Labs

MUMBAI — Lord’s Mark Industries Ltd has entered into a strategic partnership with Caribbean-based ARKALL Holdings Ltd to establish pathology laboratories and commercialize medical equipment across 28 Caribbean nations.

The regulatory disclosure, filed with BSE Limited on August 24, 2026, outlines an international expansion model designed to address the region's diagnostic infrastructure. Under internal management estimates, Lord's Mark projections target approximately $100 million in cumulative export revenue from the initiative between fiscal years 2026–27 and 2030–31.

Strategic Partnership Structure and Regional Rollout

The broad cross-border agreement combines Indian medical technology production with regional commercial operations:

• Phased Market Entry: Operations will commence in Trinidad & Tobago before progressively scaling across 28 target Caribbean markets over a three-year window.

• Capital Investment: ARKALL Holdings Ltd will finance 100% of the capital expenditure required to establish and operate the pathology lab network and handle regional market development.

• Product Supply Portfolio: Lord's Mark Industries will supply in-vitro diagnostic (IVD) kits, biochemistry reagents, medical devices, pathology laboratory equipment, and dialysis systems.

• Operational & Technical Support: Lord’s Mark will provide product registration assistance, regulatory documentation, technical guidance, and operational training.

Market Potential and Financial Breakdown

Official Sources Section

According to official filings submitted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Lord's Mark Industries confirmed that the partnership involves no related-party transactions or promoter conflicts of interest. Regulatory notifications and corporate updates are published directly via BSE Limited and the official portal of Lord's Mark Industries.

Official Statements

"Our collaboration with ARKALL Holdings Limited marks an important step in taking Lord's Mark's healthcare and MedTech capabilities to a wider international market," said Dr. Sachidanand Upadhyay, Managing Director and CEO of Lord's Mark Industries Limited. "The Caribbean expansion will allow us to combine our medical technology, pathology, and dialysis capabilities with ARKALL's regional commercial presence."

A senior management representative of ARKALL Holdings Limited stated: "Our partnership with Lord's Mark Industries Ltd brings together local market capabilities with an expanding portfolio of healthcare technologies. Beginning with Trinidad & Tobago, our objective is to build a scalable network that can progressively serve healthcare needs across the Caribbean markets."

Why It Matters

This deal expands international market footprint options for Indian healthcare and medical technology manufacturers across emerging export destinations. For healthcare consumers and providers in the Caribbean, the alliance promises expanded access to affordable diagnostic infrastructure, pathology testing, and localized dialysis equipment.

Key Facts at a Glance

• Target Revenue: Projected $100 million export revenue between FY27 and FY31.

• Geographic Scope: Pathology lab rollout across 28 Caribbean nations, starting in Trinidad & Tobago.

• Funding terms: 100% financed by partner firm ARKALL Holdings Ltd.

• Total Market Opportunity: Pathology and diagnostic market opportunity in target markets estimated at $1.24 billion.

Frequently Asked Questions

What products will Lord's Mark Industries supply in the agreement?

Lord's Mark will supply in-vitro diagnostic (IVD) products, rapid test kits, biochemistry reagents, pathology laboratory equipment, dialysis machines, and surgical technologies.

Who is financing the pathology laboratory setup costs?

ARKALL Holdings Limited is funding 100% of the investment necessary to establish and scale the pathology lab network across the Caribbean.

Are these revenue projections guaranteed?

No, the company explicitly noted in its filing that the $100 million revenue estimate represents internal management projections and forward-looking expectations subject to regulatory approvals, market rollout execution, and local commercial conditions.

Source: Official regulatory disclosures filed with BSE Limited and company announcements released by Lord's Mark Industries Limited.